R&D
NANOLEK develops over 20 generic and original products primarily in the following key areas: vaccines, chemical and biotechnology drugs, including for the treatment of rare (orphan) diseases.
NANOLEK successfully partners with leading research institutes and commercial organizations in drug development and is open for cooperation, as elaboration of original drugs features prominently in the corporate strategy.
BIOLOGICAL PRODUCTS
Discovery
Pre-clinical development
Сlinical
studies I
studies I
Сlinical
studies II
studies II
Сlinical
studies III
studies III
Registration
Approved
COVID-19
vaccine
vaccine
Rituximab
biosimilar
biosimilar
Bevacizumabum
biosimilar
biosimilar
Sabin inactivated
poliovirus vaccine
poliovirus vaccine
Pneumococcal polysaccharide
vaccine (13-valent)
vaccine (13-valent)
Quadrivalent recombinant
influenza vaccine
influenza vaccine
Human papillomavirus
vaccine (4-valent)
vaccine (4-valent)
SYNTHETICAL PRODUCTS
Discovery
Pre-clinical development
Сlinical
studies I
studies I
Сlinical
studies II
studies II
Сlinical
studies III
studies III
Registration
Approved
Hydroxychloroquine
Tretinoin
NLK-17
NLK-20
NLK-16
NLK-12
NLK-10